Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 15Parkinson Disease 4, Autosomal Dominant Lewy Body 2Metastatic Hormone-sensitive Prostate Cancer 2Urogenital Neoplasms 1Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 1Metastatic Hormone Sensitive Prostate Cancer 1Metastatic Castration-sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer 1Metastatic Castration Resistant Prostate Cancer 1Metastatic Castrate-sensitive Prostate Cancer 1Genital Neoplasms, Male 1

Interventions

Mitomycin 3Abiraterone Acetate 3motexafin gadolinium 2abiraterone 2Suspensions 2Sunitinib 2Powders 2Paclitaxel 2Gemcitabine 2Drug Therapy 2Docetaxel 2vinflunine 1valrubicin 1temsirolimus 1sipuleucel-T 1pembrolizumab 1palbociclib 1onapristone 1olaparib 1niraparib 1luprolide acetate gel depot 1gallium 68 PSMA-11 1enfortumab vedotin 1darolutamide 1atezolizumab 1apalutamide 1abemaciclib 1Watchful Waiting 1Transurethral Resection of Prostate 1Tinzaparin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Urogenital Neoplasms × Androgen Antagonists × Clear all
NCT05067140 2026-05-05

A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer

Novartis

Phase 1/2 Active not recruiting
152 enrolled
Genitourinary

Genital Neoplasms, Male, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡